Abstract:
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cause of cancer mortality. The ability to detect HNSCC an earlier stage could have significant impact on overall outcome. Previous studies demonstrated that a point-of-care (POC) lateral flow assay and an ELISA LAB test measuring CD44 and total protein (TP) aid in the diagnostic process for HNSCC. We sought to better understand the performance of the POC assay in a case control study.
Biography:
Dr. Elizabeth Franzmann, M.D. is certified by the American Board of Otolaryngology specializing in otolaryngology and head and neck surgery as an Associate Professor of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Franzmann serves as the Scientific Founder and Chief Scientific Officer of Vigilant Biosciences. Her innovative clinical research on selective salivary biomarkers for head and neck squamous cell carcinoma serves as the foundation for Vigilant Biosciences’ product line. Dr. Franzmann’s work has been funded by foundations as well as state and federal agencies with the resulting research published in numerous, well-respected, and peer-reviewed journals. Dr. Franzmann has been recognized as one of the “Best Doctors in America,” an honor that reflects fellow physicians considering her to be one of the most skilled in her field and most qualified for reviewing complex medical conditions. Dr. Franzmann received her Bachelor of Science and Doctorate of Medicine at the University of California, Los Angeles.
